Compare ABAT & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ABAT | SLN |
|---|---|---|
| Founded | 2011 | 1994 |
| Country | United States | United Kingdom |
| Employees | N/A | 88 |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 341.0M | 300.9M |
| IPO Year | 2013 | N/A |
| Metric | ABAT | SLN |
|---|---|---|
| Price | $2.37 | $11.49 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | $6.00 | ★ $42.60 |
| AVG Volume (30 Days) | ★ 3.1M | 498.4K |
| Earning Date | 05-15-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43.14 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $145.40 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.86 | $4.19 |
| 52 Week High | $11.49 | $12.19 |
| Indicator | ABAT | SLN |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
American Battery Technology Co is an integrated critical battery minerals company that develops technologies for both primary battery minerals manufacturing and lithium-ion battery recycling. It operates battery recycling facilities that process materials from electric vehicle batteries, stationary battery energy storage systems, and consumer electronics. Additionally, the company advances lithium production projects using proprietary technology to produce battery-grade lithium hydroxide. It generates revenue mainly from its recycling operations and is expanding capacity with strategic partnerships and government grants. The company's activities focus on creating a closed-loop battery materials supply chain to support sustainable manufacturing in the United States.
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.